Following Biocytogen Pharmaceuticals (Beijing) Ltd?
Get the free weekly contract digest
The latest new contracts, like Biocytogen Pharmaceuticals (Beijing) Ltd’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload BsADC Program
Jul 31, 2024•almost 2 years ago
Contract Type
agreement
BeijingBiotechnologyDescription
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. The partnership aims to explore the combination of potential first-in-class ADC and IDEAYA’s DDR small molecules to enhance the precision and potency of ADCs.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months